ProBioGen to assist manufacturing on Nobelpharma vaccine project

The company will apply its technologies and expertise to the upstream and downstream process development of Nobelpharma's vaccine for large scale manufacturing

ProBioGen has announced the signing of a service agreement for Nobelpharma’s vaccine project.

Earlier work has reportedly confirmed the versatility and benefit of ProBioGen’s vaccine development platform, consisting of its proprietary AGE1.CR.pIX suspension cell line and its cell culture medium, for the propagation of Nobelpharma’s virus strain.

Now, ProBioGen will apply its technologies and expertise to the upstream and downstream process development of Nobelpharma's vaccine for large scale manufacturing.

The duck cell line AGE1.CR.pIX was designed to serve the industrial, GMP-compliant production of a wide variety of viruses in large bioreactors and is free of any adventitious agents, ProBioGen says. It has been used for viral vector production in various clinical trials.

Companies